Table 2.
Characteristics of the 16 ART-PLH and 15 uninfected individuals included in the study.
| Donors (n=15) | HIV infected patients included in the analysis (N=17) | |
|---|---|---|
| Age (years old, (median, IQR))** | 35 [27-47.5] | 55.31 [47-60.5] |
| Gender (W/M) | 0,875 | 1 |
| Active tobacco smoking | N = 1 | |
| Delay between seropositivity and initiation of ART (days, median, IQR) | 730 [26-4440] | |
| Duration of viral load undetectability (months, median, IQR) | 68 [33-130] | |
| Last CD4 counts (/mm3) | 730 [570-827.5] | |
| Median CD4 over the last 4 years (/mm3) | 606.5 [496.5-803.5] | |
| Median CD4 nadir | 207.5 [178.5-252] | |
| Last CD4/CD8 ratio (median, IQR) | 1.05 [0.65-1.37] | |
| Antiretroviral therapy regimen | ||
| INI + NRTI | N = 7 | |
| INI + NNRTI | N = 2 | |
| NRTI + NNRTI | N = 4 | |
| NRTI + PI | N = 3 |
**: p<0,01 for the difference between uninfected individuals and ART-PLH patients (whole population, Wilcoxon non-parametric test).
INI: integrase inhibitor, NRTI: nucleosidic reverse transcriptase inhibitor, NNRTI: non-nucleosidic reverse transcriptase inhibitor, PI: protease inhibitors.